Alan P Skarbnik - Concepedia

Author

Alan P Skarbnik

Also Known As

A. P. Skarbnik, A. Skarbnik, A.P. Skarbnik, Alan P Skarbnik, Alan P Z Skarbnik, Alan P. Skarbnik, Alan P. Z. Skarbnik, Alan Pierre Zausner Skarbnik, Alan Skarbnik, Kittai, Adam S

195

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Novant Health Hackensack University Medical Center Memorial Sloan Kettering Cancer Center Georgetown University Columbia University Irving Medical Center

About

Alan P Skarbnik is an author at Novant Health specializing in oncology, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1K
2	Immunology	8	8	1K
3	Health Sciences	4	4	712
4	Blood Transplantation	2	2	116
5	Cellular Therapies	1	1	82

Alan P Skarbnik

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, The Lancet Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematology	2020	583
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Haematologica	2018	439
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL Ian W. Flinn, Peter Hillmen, Marco Montillo, Blood	2018	331
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik, Blood	2020	327
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Anthony R. Mato, Brian T. Hill, Nicole Lamanna, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaOptimal SequencingChronic Lymphocytic LeukemiaMedicine	2017	219
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience Anthony R. Mato, Chadi Nabhan, Paul M. Barr, Blood	2016	187
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States Anthony R. Mato, Meghan C. Thompson, John N. Allan, Haematologica	2018	161
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial Iván O. Rosas, George Diaz, Robert Gottlieb, Intensive Care Medicine	2021	124
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba, Nature Medicine	2024	106
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice Lindsey E. Roeker, Christopher P. Fox, Toby A. Eyre, Clinical Cancer Research	2019	89

Page 1